NCT02754219

Pharmacokinetics and Safety of Evogliptin in Subjects With Hepatic Dysfunction

A Study to Evaluate Pharmacokinetics and Safety of Evogliptin in Subjects With Hepatic Dysfunction and Control Healthy Volunteers

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 24 (actual)
• Sponsor: Dong-A ST Co., Ltd. · Industry
• Sex: All
• Age: 19 Years – 64 Years
• Healthy volunteers: Accepted

Summary

The objective of the study is to compare the pharmacokinetics profiles and safety of Evogliptin in patients wit hepatic dysfunction versus healthy volunteers after single oral dose of Evogliptin

Detailed description

When the future evogliptin be administered to liver dysfunction patients, to investgate whether dose adjustment is necessary.

Conditions

• Liver Dysfunction

Interventions

Type	Name	Description
DRUG	Evogliptin	DPP4-inhibitor, Evogliptin

Timeline

• Start date: 2016-09-22
• Primary completion: 2018-01-19
• Completion: 2018-01-19
• First posted: 2016-04-28
• Last updated: 2018-02-26

Locations

1 site across 1 country: South Korea